iBio IBIO
NASDAQ IBIO
$1.17 +0.00 (+0.00%)
As of: Sep 30, 2026 · 3:59 PM EDT

iBio (IBIO) Total Non-Current Liabilities (2022 - 2023)

Updated

iBio's Total Non-Current Liabilities came in at $24.21 million for fiscal Q1 2024 (quarter ended Sep 30, 2023), down 4.3% from the prior quarter.

Analysis

iBio (IBIO) Total Non-Current Liabilities (2022 - 2023) Analysis & Trends

At the end of FY2023 (ended Jun 30, 2023), iBio's Total Non-Current Liabilities was $25.3 million.

  • Business Quant data shows IBIO's Total Non-Current Liabilities at $25.3 million (Q4 2023), $26.21 million (Q3 2023) and $31.91 million (Q2 2023) in the three fiscal quarters before Q1 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 105.99 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 106.45 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 80.25 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 48.34 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn -967.00 Mn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 81.11 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn 36.04 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 100.86 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 5.92 Bn
10 iBio 121.75 Mn 121.75 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 24.21 Mn
Jun 30, 2023 25.30 Mn
Mar 31, 2023 26.21 Mn
Dec 31, 2022 31.91 Mn
API Access

iBio Total Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=IBIO&period=max&api_key=YOUR_API_KEY